Topic resource collection
Approved comparison material connected to this topic.
268 resourcesRead both sides
SS-31 (Elamipretide) occupies a mechanistic category that separates it from nearly every other research peptide in active development. While BPC-157 modulates angiogenic signaling and growth hormone secretagogues stimulate pituit…
GLP-1 receptor agonists. Semaglutide, tirzepatide, liraglutide. Work by mimicking glucagon-like peptide-1, an incretin hormone released by intestinal L-cells in response to food intake. These compounds bind to GLP-1 receptors in …
VIP doesn't activate GLP-1, GIP, or growth hormone secretagogue receptors. The pathways that make semaglutide, tirzepatide, and GHRP-2 effective for metabolic research. Where GLP-1 agonists slow gastric emptying and enhance insul…
Growth hormone releasing peptides (GHRPs)—GHRP-2, GHRP-6, Ipamorelin—and growth hormone secretagogues like MK-677 work through the ghrelin receptor pathway. They bind to GHSR-1a receptors in the pituitary gland, triggering pulsat…
Semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda, Victoza) work exclusively through GLP-1 receptor agonism. Binding to receptors in the hypothalamus to reduce appetite signaling and in the gut to slow gastric emptying. The …
Growth hormone secretagogues like GHRP-2, ipamorelin, and MK-677 (ibutamoren) stimulate GH release by binding ghrelin receptors (GHSR1a) in the anterior pituitary. MK-677 is orally bioavailable and produces sustained elevation in…
Here's the honest answer: oxytocin isn't comparable to most research peptides because it operates in a functionally separate domain. Trying to rank it against BPC-157, semaglutide, or TB-500 is like comparing a selective serotoni…
Here's the honest answer: most researchers conflate Lipo-C and peptides because both are sold as injectable research compounds, but the biological mechanisms are completely unrelated. Lipo-C can't activate a receptor. It provides…
Here's the honest answer: kisspeptin isn't a substitute for metabolic, growth, or regenerative peptides. And marketing that frames it as interchangeable with those compound classes misrepresents the biology. The mechanism is repr…
A 36-week Phase II trial published in The Lancet found tesofensine 0.5mg daily produced mean body weight reduction of 12.8% versus 2.0% placebo. The highest reported effect size for any pharmacological weight-loss agent tested at…
Here's the honest answer: orforglipron and injectable GLP-1 peptides don't produce identical biological effects despite targeting the same receptor. The route of administration, bioavailability, and metabolite profile differences…
Here's the honest answer: most peptide comparison content treats all peptides as interchangeable 'regenerative compounds' that broadly 'support healing' or 'promote longevity.' That's marketing language, not mechanism. Cartalax d…
VIP VPAC1, VPAC2 (G-protein coupled) Immune modulation via cAMP elevation; inhibits NF-κB, reduces pro-inflammatory cytokines (TNF-α, IL-6) Neuroinflammation, autoimmune models, vascular tone research <2 min half-life without sta…
Kisspeptin-10 (the biologically active fragment) binds GPR54 receptors in the hypothalamus to stimulate GnRH neuron depolarization. GnRH then triggers anterior pituitary release of LH and FSH, which govern testosterone production…
Lipo-C increases the hepatic availability of methyl donors and phospholipid precursors. Methionine enters the methionine cycle, where it's converted to S-adenosylmethionine (SAMe). The universal methyl donor for over 200 enzymati…
AOD-9604 Beta-3 adrenergic agonism Beta-3 adrenergic receptors (adipocytes) Direct lipolysis via cAMP → PKA → HSL activation Adipose tissue only. No BBB penetration None. Does not activate GH receptors Best choice for appetite-in…
The table below breaks down receptor targets, primary metabolic pathways, tissue-specific effects, and typical research applications across survodutide and commonly compared peptides. Survodutide GLP-1 + Glucagon Dual incretin/gl…
Oxytocin Neuropeptide modulation of social cognition, trust, and anxiety via CNS receptor binding OXTR (oxytocin receptor), cross-reactivity with V1A vasopressin receptor 3–10 minutes (IV), 20–30 minutes (intranasal) Intranasal, …
Nootropic peptides like Semax, Selank, and Cerebrolysin act on the central nervous system through neurotrophic factor upregulation, BDNF (brain-derived neurotrophic factor) expression enhancement, and synaptic plasticity modulati…
Tesofensine Triple monoamine reuptake inhibition (dopamine, norepinephrine, serotonin) Dry mouth (40%), insomnia (28%), elevated heart rate (+5 bpm mean), headache 24–48 hours for appetite suppression Contraindicated with uncontr…